Clinical trialNCT06562192RecruitingPhase 1Interventional

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

SponsorNovartis PharmaceuticalsEnrollment162Colorectal CancerHR+/HER2- Ductal and Lobular Breast CancerNon-small Cell Lung CancerPancreatic Ductal AdenocarcinomaTriple Negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

Novartis Investigative Site
Brussels, Belgium
Recruiting

Canada

Novartis Investigative Site
Toronto, Ontario, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada
Recruiting

France

Novartis Investigative Site
Bron, France
Recruiting
Novartis Investigative Site
Villejuif, France
Recruiting

Germany

Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Recruiting
Novartis Investigative Site
Essen, Germany
Recruiting
Novartis Investigative Site
München, Germany
Recruiting
Novartis Investigative Site
Rostock, Germany
Recruiting

Israel

Novartis Investigative Site
Tel Aviv, Israel
Recruiting

Italy

Novartis Investigative Site
Milan, MI, Italy
Recruiting
Novartis Investigative Site
Reggio Emilia, RE, Italy
Recruiting

Netherlands

Novartis Investigative Site
Nijmegen, Gelderland, Netherlands
Recruiting
Novartis Investigative Site
Utrecht, Netherlands
Recruiting

Spain

Novartis Investigative Site
Barcelona, Spain
Recruiting
Novartis Investigative Site
Madrid, Spain
Recruiting
Novartis Investigative Site
Madrid, Spain
Recruiting

Switzerland

Novartis Investigative Site
Geneva, Switzerland
Recruiting
Novartis Investigative Site
Lausanne, Switzerland
Recruiting

United States

Uni of Alabama at Birmingham
Birmingham, Alabama, United States
Jonathan McConathy
Recruiting
University of California la
Los Angeles, California, United States
Jonathan W Goldman
Recruiting
Stanford University Medical Center
Palo Alto, California, United States
Farshad Moradi
Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, United States
Ephraim Parent
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Shadi Abdar Esfahani
Recruiting
Bamf Health
Grand Rapids, Michigan, United States
Brandon Mancini
Recruiting
Mayo Clinic Rochester
Rochester, Minnesota, United States
Andrea Wahner Hendrickson
Recruiting
Uni of Tx Md Anderson Cancer Cntr
Houston, Texas, United States
Jordi Rodon
Recruiting
University of Washington
Seattle, Washington, United States
Delphine Chen
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Oct 2024
Primary completion: 15 Jan 2031
Completion: 16 Jan 2031
Last update posted: 8 Jul 2026
Registered enrollment: 162
Registry id: NCT06562192

Cross-registrations

EU-CTR / CTIS (EudraCT)2023-510356-23

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.